Stability of sodium valproate tablets repackaged into dose administration aids

Sodium valproate is a widely prescribed antiepileptic drug known for its therapeutic use in seizure management. Prior research has shown that this compound is sensitive to environmental factors, particularly moisture. This gap motivated the investigation of how repackaging affects drug stability. While chemical stability of sodium valproate has been studied under controlled conditions, its behavior after repackaging remains unclear. No prior work had resolved the impact of dose administration aids on tablet integrity. Storage conditions influence degradation rates of pharmaceuticals, and understanding these effects is essential for safe medication handling. Repackaging practices are common in clinical settings to improve medication adherence, but their consequences on drug quality need validation. This study addresses the need to evaluate stability in real-world repackaging scenarios.

This study aimed to assess the chemical and physical stability of sodium valproate tablets after repackaging into dose administration aids. The specific problem addressed is the potential degradation of the drug when exposed to different storage conditions. The motivation stems from reports of instability in the presence of moisture. The study sought to determine whether repackaging affects drug content and dissolution profiles. It also aimed to evaluate weight changes over time as an indicator of physical stability. The goal was to provide evidence-based guidance for clinical repackaging practices. By comparing multiple storage conditions, the study aimed to identify optimal handling protocols. The findings may help improve medication safety in clinical settings.

Sodium valproate 100 mg tablets were repackaged into dose administration aids and stored under three conditions: accelerated (40°C/75% RH), room temperature (25°C), and refrigeration (2–8°C). Samples were collected at multiple time points over 56 days for analysis. Chemical stability was assessed using high-performance liquid chromatography to measure drug content. Physical stability was evaluated by tracking weight changes. Dissolution behavior was tested using standard dissolution protocols. The study compared results across all storage conditions and time intervals. Data collection included measurements at 3, 7, 10, 14, 21, 35, 49, and 56 days. The methods focused on quantifying drug content and physical changes to assess stability.

Chemical stability of sodium valproate tablets remained within acceptable limits (90–110%) under all storage conditions for 56 days. Drug content did not fall below the threshold for potency loss during the study period. However, physical stability was compromised, with a 12.36% weight gain observed under accelerated conditions. Weight changes were most pronounced at higher temperatures and humidity. Dissolution profiles varied significantly compared to control samples. At 45 minutes of dissolution testing, half of the samples showed less than 75% drug release. The greatest variability occurred under accelerated and room temperature storage. These findings suggest that repackaging affects tablet integrity and drug release.

The study found that repackaging sodium valproate tablets into dose administration aids leads to unacceptable weight variation and altered dissolution profiles. Chemical stability remained within acceptable limits for 56 days across all storage conditions. However, physical stability was not preserved, particularly under accelerated conditions. The observed weight gain and dissolution changes suggest potential risks to medication efficacy. These findings align with the authors' claim that repackaging may compromise tablet integrity. The results highlight the need for caution in clinical repackaging practices. No prior work had resolved the extent of these effects. The authors propose that alternative packaging methods may be necessary to maintain drug quality.